Foamix Obtains India Patent for its Emollient Foam Platform – The Ideal Vehicle for Topical Drugs
Foamix Ltd., a clinical-stage specialty pharmaceutical company has announced that the company has been granted a patent from Indian Patent Office # IN 249626 entitled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent.”
This is Foamix’s third granted patent in India. Foamix already holds granted patents for its foam formulations in the United States, Canada, Australia, Mexico, New Zealand, South Africa and Israel.
"Our investors elected early on to develop a first class intellectual property portfolio with the foresight that there will be a demand for products based on our foam technology,"
Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.
The Company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix has a strong in-house pipeline. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 9 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 140 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.
For additional information please see www.foamix.co.il
Dorit Hayon, Business Development Manager, Foamix Ltd., firstname.lastname@example.org
Dov Tamarkin, CEO, Foamix Ltd., email@example.com.
# # #
Foamix Ltd. is a clinical-stage specialty pharma company, focused on the development of proprietary topical foam products, with improved convenience, higher compliance and efficacy. The Company’s technologies are backed by an extensive patent portfolio.